Leishmanicidal and Immunomodulatory Activities of the Palladacycle Complex DPPE 1.1, a Potential Candidate for Treatment of Cutaneous Leishmaniasis

Isabela B. dos Santos1, Danielle A. M. da Silva1, Fabiana A. C. R. Paz1, Daniel M. Garcia2, Adriana K. Carmona3, Daniela Teixeira1, Ieda M. Longo-Maugéri1, Simone Katz1 and Clara L. Barbiéri1*

1 Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil; 2 Departamento de Farmacologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil; 3 Departamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil

*Correspondence:
Clara L. Barbiéri
barbiieri.clara@unifesp.br

Specialty section:
This article was submitted to Antimicrobials, Resistance and Chemotherapy; a section of the journal Frontiers in Microbiology

INTRODUCTION

Leishmaniasis comprise a group of parasitic diseases displaying a wide clinical spectrum ranging from cutaneous, mucocutaneous, and visceral leishmaniasis. The World Health Organization reports a worldwide annual incidence of 0.6–1.0 million of new cases of cutaneous leishmaniasis and 50,000–90,000 of visceral leishmaniasis and 20,000–30,000 deaths occur annually...
All animals were bred and housed under specific pathogen-free conditions from Universidade Federal de São Paulo (São Paulo, Brazil). Female BALB/c mice 6–8 weeks old were acquired from breeding stocks of Anilab Company, Paulínia (São Paulo, Brazil). Antimonials, whereas amphotericin B and pentamidine represent the second-line therapy. However, toxicity, parasite resistance, high price, long treatment regimen, and mode of administration have limited the use of these compounds (Alvar et al., 2006; Polonio and Efferth, 2008; Goto and Lindoso, 2010). Other alternatives for treatment of leishmaniasis are miltefosine, paromomycin, and sitamaquine. Although these compounds have shown efficacy against cutaneous and visceral leishmaniasis, they have restricted use due to host teratogenicity, development of parasite resistance and induction of undesirables adverse effects (Thakur et al., 2000; Sundar et al., 2002; Croft and Coombs, 2003; Soto et al., 2004; Jha et al., 2005). Therefore, the development of new leishmanicidal drugs is a priority for the control of leishmaniasis and has led to the development of new synthetic and natural products extracted from plants and marine sources which have displayed different degrees of efficacy in the treatment of experimental leishmaniasis (Sen and Chatterjee, 2011; Tempone et al., 2011). More recently, several findings suggest that compounds that activate the host immune system enhance the efficacy of antileishmanial drugs (Gupta et al., 2011; Seifert et al., 2015). Antitumoral drugs have also exhibited antileishmanial activity, leading to the screening of these compounds in vitro and in clinical trials (Fuertes et al., 2008; Sanderson et al., 2014). Among antitumoral drugs, cyclopalladated complexes have shown low toxicity in animals and some of them exhibited leishmanicidal and tripanocidal activity (Caires, 2007; Navarro et al., 2008; Matsu et al., 2010; Velásquez et al., 2016). Furthermore, inhibition of cathepsin B activity has been implicated in destruction of tumoral cells by palladacycle complexes and their inhibitory effect on Leishmania cysteine proteases in vitro was also demonstrated (Bincoletto et al., 2005; Fricker et al., 2008). More recently, the effect of the palladacycle complex DPPE 1.2 on in vitro and in vivo L. (L.) amazonensis infection was reported (Paladi et al., 2012). The present study shows the action of the palladacycle complex DPPE 1.1 on promastigotes, intracellular amastigotes, and cutaneous lesions in BALB/c mice infected with L. (L.) amazonensis. Furthermore, the high efficacy of DPPE 1.1 on L. (L.) amazonensis infection in vivo is followed by the modulation of the host immune responses.

**MATERIALS AND METHODS**

**Animals**

Eight-week-old female Golden hamsters were obtained from breeding stocks of Anilab Company, Paulínia (São Paulo, Brazil). Female BALB/c mice 6–8 weeks old were acquired from Universidade Federal de São Paulo (São Paulo, Brazil). All animals were bred and housed under specific pathogen-free conditions and fed a regular diet. All animal procedures were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Brazilian National Council of Animal Experimentation. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Institutional Animal Care and Use Committee at the Federal University of São Paulo (Id # CEUA 127520).

**Parasites**

The L. (L.) amazonensis strain used (MHOM/BR/1973/M2269) was kindly provided by Dr. Jeffrey J. Shaw, Instituto Evandro Chagas, Belém, Pará, Brazil and maintained as amastigotes by inoculation into footpads of Golden hamsters every 4–6 weeks as previously described (Barbieri et al., 1990). L. (L.) amazonensis promastigotes were grown at 26°C in 199 medium (Gibco) supplemented with 4.2 mM sodium bicarbonate, 4.2 mM HEPES, 1 mM adenine, 5 mg/ml hemin (bovine type I) (Sigma-Aldrich, St. Louis, MO, United States), 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal calf serum (FCS) (Cultilab, SP, Brazil).

**Biphosphinic Palladacycle Complex [Pd_{2}(S(-)C_{2},N-DMPA)_{2}(m-DPPE)]Cl_{2}(DPPE 1.1)**

The palladacycle compound DPPE 1.1 (Figure 1) was obtained from N,N-dimethyl-1-phenethylamine (DMPA), complexed to 1,2-bis(diphenylphosphino)ethane (DPPE) ligand and synthesized as previously described (Rodrigues et al., 2003). Stock solutions at 1.0 mM were prepared in PBS after solubilization in dimethylsulfoxide (final concentration of 0.1%). For in vitro experiments, the drug was diluted to the appropriate concentration in cell culture medium, and for in vivo injections the stock was diluted in PBS.

**Effect of DPPE 1.1 on L. (L.) amazonensis Promastigotes and Intracellular Amastigotes**

The promastigote cultures at 1 × 10^6 parasites/ml were kept in 199 culture medium as described above containing between 2.5 and 50 nM of DPPE 1.1. Parasites were counted daily in a Neubauer chamber for 3 days. The leishmanicidal effect of DPPE
1.1 on intracellular amastigotes was evaluated in mouse bone marrow derived macrophages infected with *L. (L.) amazonensis*. Bone marrow-derived macrophages were generated from bone marrow stem cells isolated from BALB/c mice (Zamboni and Rabinoivitch, 2003). Cells were counted, added ($8 \times 10^5$) and cultured on glass coverslips inserted in 24-well tissue culture plates containing RPMI 1640 medium buffered with 15 mM of HEPES, 20 mM of sodium bicarbonate and supplemented with 1 mM L-glutamine, 20% of FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 30% L929 cell conditioned medium. Cultures were kept at 37°C in an atmosphere of air/CO$_2$ (95/5%). After 5 days, the medium was changed for RPMI containing 10% of FCS and macrophages were infected at a multiplicity of 2 amastigotes per macrophage. After 24 h, infected cultures were treated with different drug concentrations ($125$–$750$ nM) for 3 days. The coverslips were fixed with methanol, stained with hematoxylin-eosin and intracellular amastigotes were counted. Results are expressed by the infection index, obtained by multiplying the percentage of infected macrophages by the average number of amastigotes per macrophage. At least 200 macrophages were scored in each three coverslips. Amphoterin B at 200 nM (Sigma-Aldrich, St. Louis, MO, United States) and 1.4 mg/ml (approximately 2.76 mM) of Glucantime (Sanofi-Aventis, Brazil, 300 mg/ml, 81 mg/ml Sbv) were used as standard drugs for treatment of *L. (L.) amazonensis* promastigotes and intracellular amastigotes, respectively.

### Inhibition of *L. (L.) amazonensis* Cathepsin B by DPPE 1.1

Cathepsin activity was monitored with the fluorogenic substrate Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH (Sigma, St. Louis, MO, Cathepsin B by DPPE 1.1. The animals were euthanized 7 days after the end of each period of treatment. Parasite burden was determined by limiting dilution in foot lesions, as previously described (Lima et al., 1997) and lymphocytes were isolated from popliteal and inguinal lymph nodes for evaluation of immune responses.

### Assays for Toxicity

Serum concentrations of urea, creatinine, and transaminases were determined in BALB/c mice 7 days after the end of treatment for 10 weeks, using sets of commercial reagents (Doles Reagentes e Equipamentos para Laboratórios Ltda, Brazil).

### Evaluation of Immune Responses

The T lymphocyte population was analyzed by FACS (Afar et al., 1991). After isolation from popliteal and inguinal lymph nodes and washing with PBS, 1 $\times 10^6$ lymphocytes were fixed in formalin 1% in PBS for 30 min at 4°C, washed twice in PBS, resuspended in PBS and incubated with monoclonal antibodies either anti-CD3 conjugated to allophycocyanin, or anti-CD4 conjugated to phycoerythrin or anti-CD8 conjugated to peridinin chlorophyll protein (Pharminen). After 1 h at 4°C, they were washed twice in PBS, fixed in formalin 1% in PBS for 30 min at 4°C, washed twice in PBS, resuspended in PBS and gated on the basis of forward-angle and right-angle scatter and the fluorecense intensity was analyzed by FACS (FACSCAN—Cell Sorter Becton–Dickinson).

For evaluation of IFN-γ production, 1 $\times 10^6$ lymphocytes isolated from popliteal and inguinal lymph nodes were cultured in 200 µl of RPMI 1640 containing 20 mM NaHCO$_3$, 10 mM Heps, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 50 µM β-mercaptoethanol, 5 mM sodium pyruvate, 100 µM of non-essential amino acids solution and 10% FCS and maintained for 72 h in the presence of 50 µg/ml of *L. (L.) amazonensis* amastigote extract. Supernatants from lymphocytes cultured in the absence of parasite extract were used as a negative control. Culture supernatants were tested for IFN-γ using a double-sandwich enzyme-linked immunosorbent assay according to the manufacturer instructions (eBioscience, Inc., San Diego, CA, United States). Detection of active TGF-β was carried out in the supernatants of foot lesions from BALB/c mice isolated 7 days after the end of treatment for 5 weeks with DPPE 1.1. The animals were euthanized, and after homogenization of excised lesions in PBS, supernatants were collected, cleared by centrifugation and assayed for TGF-β by a double-sandwich ELISA assay (eBioscience, Inc., San Diego, CA, United States). Supernatant concentrations higher than the minimal values obtained from the IFN-γ and TGF-β standard were considered to be positive.

### Statistical Analysis

One-way ANOVA and Student’s *t*-test were used to determine the significant differences between groups by use of GraphPad Prism (version 5.0) and *P*-values smaller than 0.05 ($P < 0.05$) were considered significant.
RESULTS

Growth Inhibition of L. (L.) amazonensis Promastigotes by DPPE 1.1

Growth of L. (L.) amazonensis promastigotes was significantly inhibited in the presence of 2.5 to 50 nM of DPPE 1.1 after 2 and 3 days of treatment. Nearly 100% of promastigotes were killed after 2, 3, and 4 days in the presence of 20 and 50 nM of DPPE 1.1. A growth curve similar to control was observed when L. (L.) amazonensis promastigotes were cultured in the presence of the highest concentration of DMSO used for DPPE 1.1 solubilization (0.04%). Parasites were also grown in the presence of amphotericin B and after 72 of incubation the IC50 and IC90 values for both drugs were determined (Table 1).

Decrease of Infection in Macrophages Harboring L. (L.) amazonensis After Treatment With DPPE 1.1

Mouse bone marrow derived macrophages infected with L. (L.) amazonensis amastigotes for 24 h were treated with several concentrations of DPPE 1.1 ranging from 125 to 750 nM. Treatment of infected cultures with Glucantime 1.4 mg/ml was used as a positive control. Three days after incubation, infected macrophages were fixed and stained for parasite counts and determination of the infection index. A significant, dose-dependent decrease in macrophage infection was observed with an inhibition of 95% for 750 nM of DPPE 1.1 (IC50 of 227.7 nM; 95% confidence limits, 219.28–236.59 nM) (Figure 2A). Kinetics assays showed an increasing leishmanicidal effect of DPPE 1.1 at longer periods of treatment (Figure 2B). Infected cultures were also incubated with the highest concentration of DMSO used for DPPE 1.1 solubilization (0.04%) and no reduction of the viability or the infection of macrophages was observed (data not shown). The cytotoxicity of DPPE 1.1 on macrophages was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method and the CC50 was determined (1,236 nM; 95% confidence limits, 1.19–1.28 nM). Leishmanicidal effect on intracellular amastigotes was also observed in the presence of 1.4 mg/ml of Glucantime (approximately 2.76 mM) and treatment with this antimonial at concentrations higher than 1.4 mg/ml resulted in macrophage toxicity (data not shown).

DPPE 1.1 Inhibits the Cathepsin B Activity of L. (L.) amazonensis Amastigotes

DPPE 1.1 or CA074 significantly inhibited the activity of L. (L.) amazonensis extract on a most specific substrate for cathepsin B (Figure 3). A previous spectrofluorometric assay with specific substrates for cathepsins was performed and showed that although DPPE 1.1 inhibited the enzymatic activity on all of them, a significantly higher reduction on cathepsin B activity could be observed in the presence of this palladacycle complex (data not shown). These data led us to test the activity of L. (L.) amazonensis extract on a most specific substrate for cathepsin B. Figure 3 shows that the parasite proteolytic activity was significantly inhibited either by DPPE 1.1 or CA074. The calculated IC50 values for DPPE 1.1 and CA074 were not significantly different (4,413 and 4,540 µM, respectively), strongly suggesting that DPPE 1.1 inhibits L. (L.) amazonensis cathepsin B.

Reduction of Parasite Load in L. (L.) amazonensis-Infected BALB/c Mice After Treatment With DPPE 1.1

BALB/c mice infected with L. (L.) amazonensis were treated every other day with 235 mg/kg/day of DPPE 1.1 for 5 and 10 weeks injected in foot lesions. As can be observed in Figure 4, starting from 28 days of treatment the animals which received DPPE 1.1 showed a significant decrease of foot lesion size compared to controls until the end of treatment (Figures 4B,E). Parasite load was also determined by limiting dilution in foot lesions of BALB/c mice 7 days after the end of treatment for 5 and 10 weeks. Figure 4 shows that BALB/c mice treated with DPPE 1.1 displayed a significant reduction of parasite load compared to untreated animals in both periods evaluated (Figures 4F,H). To evaluate hepato and nephrotoxicity of DPPE 1.1 serum levels of transaminases, urea and creatinine were determined. No statistically significant alterations were detected between groups (Table 2).

Increase of TCD4+, TCD8+ Lymphocytes and IFN-γ Secretion and Reduction of TGF-β in L. (L.) amazonensis-Infected-BALB/c Mice After Treatment With DPPE 1.1

The analysis of T lymphocyte expression by FACS performed 5 weeks after the treatment with DPPE 1.1 showed a significant increase of TCD4+ and TCD8+ lymphocytes in BALB/c mice treated with DPPE 1.1 compared to control group (Figure 5A and Supplementary Figure S1). At the same period of treatment secretion of IFN-γ and TGF-β was also evaluated. A significant increase of IFN-γ secretion was observed in mice treated with DPPE 1.1 compared to untreated animals (Figure 5B). High levels of active TGF-β were detected in the foot lesions from mice that received PBS in contrast to those treated with DPPE 1.1 that displayed a significant reduction of TGF-β production (Figure 5C).

DISCUSSION

The present study showed the in vitro and in vivo activity of the palladacycle complex DPPE 1.1 on L. (L.) amazonensis.

| Drug            | IC50 (nM) | CI 95%          | IC90 |
|-----------------|-----------|----------------|------|
| DPPE 1.1        | 2.72      | 2.649–2.8022   | 5.99 |
| Amphotericin B  | 27.36     | 22.08–33.88    | 142.3|

TABLE 1 | In vitro activity of DPPE 1.1 and amphotericin B on L. (L.) amazonensis promastigotes.
The *in vitro* leishmanicidal action of DPPE 1.1 was firstly demonstrated on *L. (L.) amazonensis* promastigotes which were destroyed at nanomolar concentrations of DPPE 1.1 with IC\textsubscript{50} value 10-fold lower than that of Amphotericin B. This palladacycle complex also displayed an effective leishmanicidal activity on intracellular amastigotes (IC\textsubscript{50} = 227.7 nM), while was fivefold less toxic to macrophages (CC\textsubscript{50} = 1,236 nM). Similar leishmanicidal effect was also observed with Glucantime, but at significantly higher concentrations compared to those used with DPPE 1.1. The antipROTOZOAL action of DPPE 1.1 was previously demonstrated on *Trypanosoma cruzi* which was destroyed with lower concentrations of this palladacycle complex compared to benznidazole, the main drug available for the treatment of Chagas' disease (Matsuo et al., 2010). Other palladacycles were tested against *Leishmania* and showed an effective activity only on promastigote growth (Fricker et al., 2008) and previous data from our group showed the *in vitro* and *in vivo* efficacy of the palladacycle complex DPPE 1.2 on *L. (L.) amazonensis* (Paladi et al., 2012). More recently the leishmanicidal activity of a series of palladacycles on intracellular amastigotes of *L. (L.) amazonensis* was also demonstrated and among them a binuclear palladacycle complex named CP2 showed an effective action on *L. (L.) amazonensis* infection (Velásquez et al., 2016, 2017). The leishmanicidal activity of DPPE 1.1 is comparable to that observed with CP2. However, a concentration 44-times higher of CP2 was used to destroy *L. (L.) amazonensis* amastigotes *in vitro* in comparison to DPPE 1.1 (Velásquez et al., 2017).

The leishmanicidal effect of DPPE 1.1 was also demonstrated *in vivo*. Treatment with 3.5 and 7 mg/kg of DPPE 1.1 led to a reduction of parasite load in foot lesions of 93 and 99%, respectively. In comparison with *in vivo* treatment with CP2, our data indicate the higher efficacy of DPPE 1.1 over this cyclopalladated compound since at the same concentration (7 mg/kg) mice treated with DPPE 1.1 and CP2 displayed a decrease of parasite load of 99 and 55%, respectively.

**FIGURE 2** (A) Activity of DPPE 1.1 on *L. (L.) amazonensis*-infected macrophages. Mouse bone marrow derived macrophages infected with amastigotes of *L. (L.) amazonensis* were treated with the drugs for 3 days and the infection index was estimated. *P* < 0.001 compared to control. (B) Kinetics of DPPE 1.1 leishmanicidal activity on *L. (L.) amazonensis*-infected macrophages. Mouse bone marrow derived macrophages were infected with amastigotes of *L. (L.) amazonensis*, treated with the drugs for 3, 5, and 7 days and the infection index was calculated after each period. *P* < 0.001 compared to control; P < 0.05 compared to treatment with DPPE 1.1 500 nM.

**FIGURE 3** Effect of DPPE 1.1 on proteolytic activity of *L. (L.) amazonensis*. Fluorogenic substrate specific for cathepsin B-like proteases was incubated with extracts of *L. (L.) amazonensis* amastigotes in presence of increasing concentrations of DPPE 1.1 (A) or CA074 (B).
FIGURE 4 | Effect of DPPE 1.1 on BALB/c mice infected with *L. (L.) amazonensis*. Macroscopic evaluation of lesions in untreated mice (A,C), mice treated with DPPE 1.1 for 5 (3.5 mg/Kg) (B) and 10 weeks (7.0 mg/Kg) (D). Development of foot lesions in *L. (L.) amazonensis*-infected BALB/c mice treated with DPPE 1.1 for 5 (E) and 10 weeks (G). Parasite load in foot lesions of *L. (L.) amazonensis*-infected BALB/c mice treated with DPPE 1.1 for 5 (F) and 10 weeks (H). *P < 0.05. Data are representative of three independent experiments.

TABLE 2 | Serum concentrations of transaminases, urea, and creatinine in *L. (L.) amazonensis*-infected BALB/c mice 7 days after treatment with either PBS or DPPE 1.1 for 10 weeks.

| Groups  | Biochemical markers | Concentration | Reference values |
|---------|---------------------|---------------|------------------|
| PBS     | AST                 | 13.968 UI/L   | 12–42 UI/L       |
| DPPE 1.1| AST                 | 13.531 UI/L   |                  |
| PBS     | ALT                 | 9.856 UI/L    | 8–42 UI/L        |
| DPPE 1.1| ALT                 | 12.863 UI/L   |                  |
| PBS     | Urea                | 18.98 mg/dL   | 15–40 mg/dL      |
| DPPE 1.1| Urea                | 24.36 mg/dL   |                  |
| PBS     | Creatinine          | 0.96 mg/dL    | 0.5–1.1 mg/dL    |
| DPPE 1.1| Creatinine          | 0.74 mg/dL    |                  |

(Velásquez et al., 2017). Furthermore, treatment with DPPE 1.1 did not result in toxicity in *L. (L.) amazonensis*-infected BALB/c mice as demonstrated by hepatic and renal assays after treatment with this compound, corroborating literature data that showed the low toxicity of these palladacycle complexes in the treatment of mice against tumor cells (Rodrigues et al., 2003). Although the treatment with DPPE 1.1 resulted in a high reduction of parasite load in foot lesions (93 and 99%), there was no a sterile cure in treated mice. However, it is important to note that the BALB/c strain is highly susceptible to *L. (L.) amazonensis* infection and mimics the anergic form of diffuse cutaneous leishmaniasis caused by this parasite (Andrade et al., 1984; Lainson and Shaw, 1987).

The inhibitory activity of palladacycle complexes on the cysteine protease cathepsin B of tumoral cells was reported and this property has been related, at least in part, to the antitumoral activity of these compounds (Bincoletto et al., 2005). We showed that DPPE 1.1 inhibited the high cathepsin B activity expressed in *L. (L.) amazonensis* amastigotes. The inhibitory effect of the palladacycle complex DPPE 1.2 on *L. (L.) amazonensis* cathepsin B activity was also demonstrated (Paladi et al., 2012). Although the involvement of cathepsin L-like and cathepsin B-like in *Leishmania* growth and virulence has been demonstrated in vitro and in vivo (Mottram et al., 1996, 1998; Bart et al., 1997), the relevance of the cathepsin B activity inhibition for destruction of *L. (L.) amazonensis* by DPPE 1.1 in treated mice needs to be further explored. Other possible relevant targets which have been associated to the action of palladacycles against tumor cells are their effects on the lysosomal and mitochondrial permeabilization that can trigger apoptosis (Barbosa et al., 2006; Santana et al., 2009).

The treatment of *L. (L.) amazonensis*-infected BALB/c mice with DPPE 1.1 was followed by the activation of the immune system as shown by the increase of TCD4+ and TCD8+ lymphocytes and the higher frequency of lymphocytes producing IFN-γ in treated animals. The participation of the immune system was also demonstrated in *L. (L.) amazonensis*-infected mice treated with the palladacycle complex DPPE 1.2 (Paladi et al., 2017). TGF-β was significantly reduced in mice after the treatment with DPPE 1.1. TGF-β is an...
imunosuppressor cytokine known to exacerbate visceral and cutaneous leishmaniasis (Barral-Netto et al., 1992; Rodrigues et al., 1998; Wilson et al., 1998; Pinheiro et al., 2005). The present data corroborate these findings since low levels of TGF-β were detected in foot lesions from mice treated with DPPE 1.1 followed by a significant increase of CD4+ and CD8+ T lymphocytes and IFN-γ secretion. Literature data have also demonstrated that TGF-β is an important factor in the matrix formation and stimulation of collagen production, playing a key role in the acceleration of wound healing in cutaneous leishmaniasis (Abdoli et al., 2017). In the present study the collagen production was not analyzed. However, our data seem not support this hypothesis since in mice treated with DPPE 1.1 there was a significant decrease of TGF-β. Data on IFN-γ production suggest the participation of this cytokine in mice treated with DPPE 1.1. Although the involvement of CD4+ Th1 lymphocytes producing IFN-γ has been demonstrated in mice protected against L. (L.) amazonensis infection (Coelho et al., 2003; Campbell et al., 2004; Pinto et al., 2004), our previous data showed that the strain of L. (L.) amazonensis used in the present study is unresponsive to nitric oxide secreted by activated macrophages (Carmo et al., 2010). Furthermore, literature data have shown that it is controversial the susceptibility of L. (L.) amazonensis to nitric oxide secreted by activated macrophages (Qi et al., 2004; Mukbel et al., 2007). Therefore, it is possible that cytotoxic CD8+ lymphocytes play a more relevant role in destruction of L. (L.) amazonensis in mice treated with DPPE 1.1, corroborating previous data which showed the participation of cytotoxic CD8+ T lymphocytes in L. (L.) amazonensis infection (Colmenares et al., 2003; Alves et al., 2004; Pereira and Alves, 2008; Pereira et al., 2011; Souza-Silva et al., 2014). Furthermore, our previous data showed an increase of CD8+ T lymphocytes parallel to their cytotoxic activity on L. (L.) amazonensis-infected macrophages (Fedeli et al., 2010).

CONCLUSION

In conclusion, the leishmanicidal and immunomodulatory activity of DPPE 1.1 against L. (L.) amazonensis infection at concentrations non-toxic to the host support further studies to explore the potential of this palladacycle complex as an additional option to available chemotherapies for leishmaniasis.
AUTHOR CONTRIBUTIONS

IS, DS, FP, AC, DT, and SK designed and performed the experiments, analyzed and interpreted the data. DG designed, synthesized, and analyzed the compound. IL-M analyzed and interpreted the data and contributed to reviewing of manuscript. CB conceived the work, contributed to interpretation of data, wrote and reviewed the manuscript.

FUNDING

This work was supported by grant #2013/02133-8, São Paulo Research Foundation (FAPESP). DS (2014/06935-4) was supported by FAPESP fellowship.

REFERENCES

Abdoli, A., Maspí, N., and Ghaffarifar, F. (2017). Wound healing in cutaneous leishmaniasis: a double edged sword of IL-10 and TGF-β. Comp. Immunol. Microbiol. Infect. Dis. 51, 15–26. doi: 10.1016/j.cimid.2017.02.001

Afar, B., Merrill, J., and Clark, E. A. (1991). Detection of lymphocyte subsets using three-color/single-laser flow cytometry and the fluorescent dye peridinin-chlorophyll-alpha protein. J. Clin. Immunol. 11, 254–261. doi: 10.1007/BF00918183

Alvar, J., Croft, S., and Olliaro, P. (2006). Chemotherapy in the treatment and control of leishmaniasis. Adv. Parasitol. 61, 223–274. doi: 10.1016/S0065-308X(05)60006-8

Alves, C. R., Benévelo-de-Andrade, T. C., Alves, J. L., and Pirmez, C. (2004). Lysosomal depletion in K562 leukaemia cells. Curr. Med. Chem. 11, 137–148.

Barbieri, C. L., Doine, A. I., and Freymuller, E. (1984). Immunopathology of experimental cutaneous leishmaniasis. Am. J. Pathol. 114, 137–148.

Barbiéri, C. L., Doine, A. I., and Freymuller, E. (1990). Lysosomal deplacement in macrophages from spleen and foot lesions of Leishmania-infected hamster. Exp. Parasitol. 71, 218–228. doi: 10.1016/0014-4894(90)90024-7

Barbosa, C. M., Oliveira, C. R., Nascimento, F. D., Smith, M. C., Fausto, D. M., Soufen, M. A., et al. (2006). Biphosphinic palladacycle complex mediates lysosomal membrane permeabilization and cell death in K362 leukaemia cells. Eur. J. Pharmacol. 542, 37–47. doi: 10.1016/j.ejphar.2006.06.004

Barral-Netto, M., Barral, A. C. E., Stegk, Y. A., Ellingsworth, L. R., Twardzik, D. R., et al. (1992). Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257, 454–456. doi: 10.1126/science.1636092

Bart, G., Frame, M. J., Carter, R., Coombs, G. H., and Mottram, J. C. (1997). Cathespin B-like cysteine protease-deficient mutants of Leishmania mexicana. Mol. Biochem. Parasitol. 88, 53–61. doi: 10.1016/S0166-6851(97)00072-8

Bincoleto, C., Tersariol, I. L., Oliveira, C. R., Dreher, S., Fausto, D. M., Souffen, M. A., et al. (2005). Chiral cyclcopalladated complexes derived from N,N-dimethyl-1-phenethylamine with bridging bis(diphenylphosphine)ferrocene ligand as inhibitors of the cathespin B activity and as antitumor agents. Bioorg. Med. Chem. 13, 3047–3055. doi: 10.1016/j.bmc.2005.01.057

Caires, A. C. F. (2007). Recent advances involving palladium (II) complexes for cancer therapy. Anticancer Agents Med. Chem. 7, 484–491. doi: 10.2174/187152007781668661

Campbell, K., Popov, V., and Soong, L. (2004). Identification and molecular characterization of a gene encoding a protective Leishmania amazonensis Trp-Asp (WD) protein. Infect. Immun. 72, 2194–2202. doi: 10.1128/IAI.72.4.2194-2202.2004

ACKNOWLEDGMENTS

We are grateful to Michel Rabinovitch for critical review of the manuscript, for pertinent suggestions and helpful discussions.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2018.01427/full#supplementary-material

FIGURE S1 | Gate strategy of the T lymphocyte subsets from popliteal and inguinal lymph nodes obtained of control and group treated with DPPE 1.1. (A) Dot plot forward scatter (FSC) × side scatter (SSC) gated on lymphocyte population. (B) Dot plot gated on CD3+ cells. (C) Dot plot gated on CD4+ and CD8+.
Paladi, C. S., Silva, D. A. M., Motta, P. D., Garcia, D. M., Teixeira, D., Paladi, C. S., Pimentel, I. A. S., Katz, S., Cunha, R. L. O. R., Judice, W. A. S., Caires, P. R. A. S., Silva, F. S., Rebello, K. M., Marín-Villa, M., Traub-Czeko, A. L., Silva, L. S., Torrecilhas, A. C., Pascoalino, B. S., Ramos, T. C., Pinheiro, R. O., Pinto, E. F., Lopes, J. R., Guedes, H. L., Fentanes, R. F., and Rodrigues, E. G., Silva, L. S., Fausto, D. M., Hayashi, M. S., Dreher, S., and Santos, R. O. (2008). Immunological characteristics of Mukbel, R. M., Patten, C., Gibson, K., Ghosh, M., Petersen, C., and Jones, D. E. Mottram, J. C., Souza, A. E., Hutchison, J. E., Carter, R., Frame, M. J., and Coombs, G. H. (1996). Evidence from disruption of the lmcpb gene array of Leishmania (L.) spp. infections with a combination of a palladacycle complex and low dose of liposomal amphotericin B and a novel DNA vaccine candidate. Antimicrob. Agents Chemother. 59, 5819–5823. doi: 10.1128/AAC.00727-15 Sen, R., and Chatterjee, M. (2011). Plant derived therapeutics for the treatment of Leishmaniasis. Phytomedicine 18, 1056–1069. doi: 10.1016/j.phymed.2011.03.004

Soto, J., Arana, B. A., Toledo, J., Rizzo, N., Veja, J. C., Diaz, A., et al. (2004). Miltefosine for New World cutaneous leishmaniasis. Clin. Infect. Dis. 38, 1266–1272. doi: 10.1086/383321 Souza-Silva, F., Pereira, B. A. S., Finkelstein, L. C., Zucolotto, V., Caffarena, E. R., and Alves, C. R. (2014). Dynamic identification of H2 epitopes from Leishmania (Leishmania) amazonensis cytochrome B with potential immune activity during murine infection. J. Mol. Recognit. 27, 98–105. doi: 10.1002/jmr.2334 Sundar, S., Iha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., et al. (2002). Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347, 1739–1746. doi: 10.1056/NEJMoa021556 Tampone, A. G., Oliveira, C. M., and Berlinc, R. G. (2011). Current approaches to detect novel antileishmanial natural products. Planta Med. 77, 572–585. doi: 10.1055/s-0030-1250663 Thakur, C. P., Kanyok, T. P., Pandey, A. K., Sinha, G. P., Zaniewski, A. E., Houlihan, H. H., et al. (2000). A prospective randomized, comparative, openlabel trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94, 429–431. doi: 10.1016/s0035-9203(00)0130-5 Velásquez, A. M. A., Ribeiro, W. C., Venn, V., Castelli, S., Camargo, M. S., Assis, R. P., et al. (2017). Efficacy of a binuclear cyclolalypadated compound for therapy of cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis and its inhibitory effect on topoisomerase IB. Antimicrob. Agents Chemother. 61, e00688-17. doi: 10.1128/AAC.00688-17

Velásquez, A. M. A., Souza, R. A., Passalacqua, T. G., Ribeiro, A. R., Scontri, M., Chin, C. M., et al. (2016). Antiprotozoal activity of the cyclolalypadated complexes against Leishmania amazonensis and Trypanosoma cruzi. J. Braz. Chem. Soc. 27, 1032–1039. doi: 10.5935/0103-5053.20150360 WHO (2017). Leishmaniasis Fact Sheet Updated April 2017. Available at: http://www.who.int/mediacentre/factsheets/fs375/en/ Wilson, M. E., Young, B. M., Davidson, B. L., Mente, K. A., and McGowan, S. E. (1998). The importance of TGF-β in murine visceral leishmaniasis. J. Immunol. 161, 6148–6155. Zamboni, D. S., and Rabinovitch, M. (2003). Nitric oxide partially controls Coxiiella burnetii phase II infection in mouse primary macrophages. Infect. Immun. 71, 1225–1233. doi: 10.1128/IAI.71.3.1225-1233.2003

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2018 dos Santos, da Silva, Paz, Garcia, Carmona, Teixeira, Longo-Maugeri, Katz and Barbieri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.